Document Detail

Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells.
MedLine Citation:
PMID:  16765944     Owner:  NLM     Status:  MEDLINE    
The chaperonin CCT hexadecamer is required for the folding of non-native actins and tubulins in eukaryotic cells. Among the consequences of greatly reducing CCT holocomplex levels in human cell lines by siRNA targeting are growth arrest and changes in cell morphology and motility. Less extensive reduction of CCT activity via microinjection of an inhibitory anti-CCT epsilon subunit monoclonal antibody, which alters the rates of substrate processing by CCT in vitro, causes a delay in cell cycle progression through G1/S phase in synchronized Swiss 3T3 cells. The degree of growth arrest strongly correlates with the extent of CCT depletion, indicating that full CCT activity is required for normal cell growth and division. Depletion of CCT does not affect actin polypeptide synthesis but causes a reduction in levels of native actin and perturbation of actin-based cell motility in BE cells. There are no large-scale effects on cytoplasmic protein synthesis or a general heat shock response during periods of low CCT activity.
Julie Grantham; Karen I Brackley; Keith R Willison
Related Documents :
8100414 - Intracellular degradation and reduced cell-surface expression of sucrase-isomaltase in ...
14567784 - A simple technique for reducing edge effect in cell-based assays.
1203034 - Effects of shock on the pancreatic acinar cell. cellular and subcellular effects in hum...
12591194 - In vitro culture of glugea sp.
20093404 - Cd44 activation in mature b-cell malignancies by a novel recurrent igh translocation.
3356134 - Seasonal variations of dna-synthesis in intestinal epithelial cells of hibernating anim...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Experimental cell research     Volume:  312     ISSN:  0014-4827     ISO Abbreviation:  Exp. Cell Res.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-07-20     Completed Date:  2006-08-31     Revised Date:  2011-11-02    
Medline Journal Info:
Nlm Unique ID:  0373226     Medline TA:  Exp Cell Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2309-24     Citation Subset:  IM    
Cancer Research UK Centre for Cell and Molecular Biology, Chester Beatty Laboratories, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Actins / biosynthesis,  metabolism
Antibodies, Monoclonal / pharmacology
Apoptosis / physiology
Cell Cycle / drug effects,  physiology*
Cell Cycle Proteins / metabolism
Cell Line, Tumor
Cell Movement / physiology
Cell Proliferation
Chaperonin Containing TCP-1
Chaperonins / genetics,  immunology,  metabolism*
Cyclin E / biosynthesis
Cytoskeleton / drug effects,  metabolism*
HSP90 Heat-Shock Proteins / metabolism
Hela Cells
Microfilaments / metabolism
Microtubules / metabolism
Protein Biosynthesis / genetics
Protein-Serine-Threonine Kinases / metabolism
Proto-Oncogene Proteins / metabolism
RNA, Small Interfering / genetics
Swiss 3T3 Cells
Tubulin / biosynthesis,  metabolism
Reg. No./Substance:
0/Actins; 0/Antibodies, Monoclonal; 0/CCT5 protein, human; 0/Cell Cycle Proteins; 0/Cyclin E; 0/HSP90 Heat-Shock Proteins; 0/Proto-Oncogene Proteins; 0/RNA, Small Interfering; 0/Tcp1 protein, mouse; 0/Tubulin; EC Kinases; EC kinase 1; EC 3.6.1.-/Chaperonin Containing TCP-1; EC 3.6.1.-/Chaperonins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apop...
Next Document:  A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing.